Media coverage about Flex Pharma (NASDAQ:FLKS) has been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Flex Pharma earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 48.3036208904814 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the headlines that may have effected Accern’s analysis:
- Flex Pharma, Inc. (FLKS) Stock Rating Upgraded by Zacks Investment Research (americanbankingnews.com)
- Zacks: Brokerages Expect Flex Pharma, Inc. (NASDAQ:FLKS) to Post -$0.68 EPS (americanbankingnews.com)
- Jefferies Group Comments on Flex Pharma, Inc.’s FY2017 Earnings (NASDAQ:FLKS) (americanbankingnews.com)
- Edited Transcript of FLKS earnings conference call or presentation 2-Aug-17 12:45pm GMT (finance.yahoo.com)
- Flex Pharma, Inc. (FLKS) Posts Quarterly Earnings Results, Beats Estimates By $0.12 EPS (americanbankingnews.com)
Shares of Flex Pharma (NASDAQ FLKS) traded down 2.39% during midday trading on Tuesday, reaching $3.67. 18,157 shares of the company’s stock traded hands. The stock has a 50 day moving average of $3.92 and a 200-day moving average of $3.96. Flex Pharma has a 12 month low of $3.01 and a 12 month high of $12.68. The stock’s market cap is $62.86 million.
Flex Pharma (NASDAQ:FLKS) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.12. The firm had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $0.46 million. Flex Pharma had a negative net margin of 2,410.97% and a negative return on equity of 64.15%. On average, equities research analysts forecast that Flex Pharma will post ($2.42) EPS for the current fiscal year.
A number of equities analysts recently weighed in on the stock. Zacks Investment Research raised shares of Flex Pharma from a “sell” rating to a “hold” rating in a research note on Monday. Jefferies Group LLC reduced their target price on shares of Flex Pharma from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, May 4th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Flex Pharma currently has an average rating of “Buy” and an average target price of $15.40.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Flex Pharma (NASDAQ:FLKS) Stock Price” was originally reported by BBNS and is the property of of BBNS. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://baseballnewssource.com/markets/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-flex-pharma-nasdaqflks-stock-price/1409581.html.
About Flex Pharma
Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
Receive News & Ratings for Flex Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma Inc. and related companies with our FREE daily email newsletter.